Twenty-Five Years of FDA Prescription-to-Nonprescription Switch Approvals (2001–2025)

The U.S. Food and Drug Administration Prescription-to-Nonprescription (Rx-to-OTC) switch pathway enables consumers to access safe and effective medications without healthcare supervision. Data were extracted from the FDA Prescription-to-Nonprescription Switch List and corresponding New Drug Applications available through Drugs@FDA. All switches approved between 2001 and 2025 and listed in the FDA registry at the time of extraction were analyzed by active ingredient, therapeutic area, indication, year, route of administration, dosage form, strength, and switch type. A total of 45 Rx-to-OTC switches representing 30 unique active ingredients were identified. The Allergy/Respiratory category accounted for 56% of all approvals, followed by Ophthalmology (11%) and Gastrointestinal (11%). Oral formulations were most frequent (58%), with nasal (16%), ophthalmic (11%), topical (11%), and transdermal (4%) routes representing smaller shares. Full switches comprised 64% of all cases, partial switches represented 27%, and direct nonprescription NDAs listed within the registry 9%. From 2001 to 2025, the FDA’s Rx-to-OTC switches demonstrate sustained activity in well-established therapeutic areas with gradual expansion into categories of broader public health relevance. Implementation of the 2024 Additional Conditions for Nonprescription Use framework may influence future switch considerations by permitting structured safeguards beyond traditional labeling to support safe consumer self-selection.